COMPASS Pathways Plc American Depository Shares (CMPS)
NASDAQ: CMPSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 11.90 +1.80%
CMPS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.62B
- EPS (TTM)
- -$3.76
- Dividend yield
- None
- 52-week range
- 4.88 – 15.87
- Day range
- 11.45 – 11.86
- Volume / Avg
- 1.58M / 3.13M
- Beta
- —
- Shares outstanding
- 138.48M
- Next earnings
- Nov 3, 2026
52-week range
CMPS stock today
COMPASS Pathways Plc American Depository Shares (CMPS) closed at $11.69 on Oct 7, up 1.12% (+$0.13), versus the S&P 500's 0.22% decline. Shares are 26.3% below their 52-week high of $15.87, set on Sep 9, 2026 and 139.5% above the 52-week low of $4.88, in the middle of the past year's range. CMPS is up 69.4% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 87.3%.
COMPASS Pathways Plc American Depository Shares has posted a net loss over the last twelve months (EPS of -$3.76), so its P/E ratio is not meaningful. COMPASS Pathways Plc American Depository Shares's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About COMPASS Pathways Plc American Depository Shares
Company profileCOMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kabir Kumar Nath M.A., M.B.A.
- Headquarters
- London
- Employees
- 156
- IPO year
- 2020
- Website
- compasspathways.com
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$23.75+103.17%
- Strong buy 3
- Buy 12
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.42
COMPASS Pathways Plc American Depository Shares peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| QUREuniQure N.V. | 23.14 | +0.35% | $1.61B | vs CMPS |
| OCULOcular Therapeutix Inc. | 7.23 | -1.50% | $1.59B | vs CMPS |
| ETONEton Pharmaceuticals Inc. | 54.88 | +0.20% | $1.57B | vs CMPS |
| STOKStoke Therapeutics Inc. | 24.29 | -0.33% | $1.57B | vs CMPS |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs CMPS |
| PAHCPhibro Animal Health Corporation Class A | 37.72 | +3.03% | $1.53B | vs CMPS |
| BRVEBraveheart Bio Inc. | 18.58 | -6.11% | $1.67B | vs CMPS |
| INVAInnoviva Inc. | 21.06 | +1.10% | $1.52B | vs CMPS |
Indexes, lists and sector
COMPASS Pathways Plc American Depository Shares stock FAQ
What is COMPASS Pathways Plc American Depository Shares's stock price today?
CMPS last traded at $11.69 as of Oct 7, 4:00 PM EDT, up 1.12% on the day. Prices are delayed at least 15 minutes.
When is COMPASS Pathways Plc American Depository Shares's next earnings date?
COMPASS Pathways Plc American Depository Shares is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.42.
Who is COMPASS Pathways Plc American Depository Shares's CEO?
Mr. Kabir Kumar Nath M.A., M.B.A. is the chief executive officer of COMPASS Pathways Plc American Depository Shares, which has about 156 employees.
What is the CMPS 52-week high?
The 52-week high for CMPS is $15.87 and the 52-week low is $4.88. The stock is currently 26.3% below its high.